Oral HCV therapy hailed a ‘huge advance’

Boceprevir (VictreIis, MSD) has received TGA approval as an add-on treatment for patients with genotype 1  – the most common form – of HCV.

The drug, a protease inhibitor, is indicated for use alongside combination peginterferon alfa and ribavirin in adults who are previously untreated or who have failed previous therapy.

Associate Professor Simone Strasser, chair of the Gastroenterological Society of Australia’s Digestive Health Foundation, said it should lead to more patients achieving a sustained virological response.

“This is a huge advance in the treatment of hepatitis C for patients with genotype 1 infection,” Professor Strasser told MO.

“We’re going from being able to cure between 40–50% of patients that we treat with genotype 1 infection up to about two-thirds of patients, if not more, being able to be cured.”

Cure was defined as achievement of